Gloria Diaz
Family · Wilmington, DENPI 1891808143
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 515 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 515 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Pfizer$965
- Novo Nordisk$857
- AstraZeneca$796
- Lilly USA, LLC$429
- AbbVie$380
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,95998%
- Education$1262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 107 | $1,309 |
| Pfizer | 81 | $965 |
| Novo Nordisk | 61 | $857 |
| AstraZeneca | 30 | $796 |
| Lilly USA, LLC | 25 | $429 |
| AbbVie | 23 | $380 |
| Boehringer Ingelheim | 20 | $379 |
| Biohaven Pharmaceuticals, Inc. | 19 | $337 |
| Alkermes, Inc. | 14 | $285 |
| Amgen | 15 | $275 |
| Biohaven Pharmaceutical Holding Company Ltd. | 23 | $266 |
| Astellas Pharma US Inc | 11 | $263 |
| Teva Pharmaceuticals USA, Inc. | 11 | $212 |
| Ardelyx, Inc. | 16 | $204 |
| Kowa Pharmaceuticals America, Inc. | 14 | $188 |
| Merck | 8 | $118 |
| Exact Sciences | 5 | $117 |
| GSK | 7 | $113 |
| Sanofi-aventis U.S. LLC | 4 | $97 |
| Tactile Systems Technology Inc | 3 | $81 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Redhill Biopharma Inc. | 1 | $50 |
| VBI Vaccine (delaware) Inc. | 2 | $48 |
| Sanofi | 1 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Smith+Nephew | 1 | $23 |
| Alvogen Inc | 1 | $23 |
| Bayer | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Cipher Pharmaceuticals US LLC | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,085 in reported general payments places this provider in the 95th percentile of 523 family providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $76,177 |
| JardianceEmpagliflozin | 63 | $60,127 |
| ProliaDenosumab | 18 | $30,531 |
| TrulicityDulaglutide | 23 | $22,436 |
| JanuviaSitagliptin Phosphate | 19 | $21,864 |
| FarxigaDapagliflozin Propanediol | 16 | $16,222 |
| GlyxambiEmpagliflozin/Linagliptin | 18 | $12,277 |
| TradjentaLinagliptin | 15 | $9,914 |
| VeozahFezolinetant | 11 | $6,089 |
| Cinacalcet Hcl | 13 | $5,448 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $4,239 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 12 | $2,589 |
| Rosuvastatin Calcium | 141 | $2,116 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 15 | $2,058 |
| Gabapentin | 83 | $1,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $379 | $82,31896 claims |
| Novo NordiskOzempic | $857 | $76,17774 claims |
| AmgenProlia | $275 | $30,53118 claims |
| Lilly USA, LLCTrulicity | $429 | $22,43623 claims |
| MerckJanuvia | $118 | $21,86419 claims |
| AstraZenecaFarxiga | $796 | $16,22216 claims |
| Astellas Pharma US IncVeozah | $263 | $6,08911 claims |
| GSKShingrix | $113 | $2,58912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 523 family providers in Delaware.
Other family in Wilmington
- Tracy EstesWilmington$59K
- Jodi KahanWilmington$21K
- Elizabeth Sharp-AsiyoWilmington$13K
- Shannon HogateWilmington$10K
- Carolyn BarrettWilmington$10K
- Amy HitchensWilmington$8K
- Emmanuel AntonioWilmington$7K
- Stephanie Evans MitchellWilmington$6K
- Sidonie SalmonWilmington$6K
- Laruen GutierrezWilmington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.